Jointown Pharmaceutical Group Balance Sheet Health
Financial Health criteria checks 6/6
Jointown Pharmaceutical Group has a total shareholder equity of CN¥30.9B and total debt of CN¥16.0B, which brings its debt-to-equity ratio to 51.7%. Its total assets and total liabilities are CN¥97.2B and CN¥66.4B respectively. Jointown Pharmaceutical Group's EBIT is CN¥4.2B making its interest coverage ratio 4. It has cash and short-term investments of CN¥14.6B.
Key information
51.7%
Debt to equity ratio
CN¥15.96b
Debt
Interest coverage ratio | 4x |
Cash | CN¥14.55b |
Equity | CN¥30.86b |
Total liabilities | CN¥66.38b |
Total assets | CN¥97.24b |
Recent financial health updates
Recent updates
These 4 Measures Indicate That Jointown Pharmaceutical Group (SHSE:600998) Is Using Debt Reasonably Well
Aug 01Jointown Pharmaceutical Group (SHSE:600998) Has More To Do To Multiply In Value Going Forward
Jun 07Jointown Pharmaceutical Group Co., Ltd's (SHSE:600998) Earnings Are Not Doing Enough For Some Investors
May 21Calculating The Intrinsic Value Of Jointown Pharmaceutical Group Co., Ltd (SHSE:600998)
Apr 05Financial Position Analysis
Short Term Liabilities: 600998's short term assets (CN¥79.8B) exceed its short term liabilities (CN¥63.5B).
Long Term Liabilities: 600998's short term assets (CN¥79.8B) exceed its long term liabilities (CN¥2.9B).
Debt to Equity History and Analysis
Debt Level: 600998's net debt to equity ratio (4.6%) is considered satisfactory.
Reducing Debt: 600998's debt to equity ratio has reduced from 86.1% to 51.7% over the past 5 years.
Debt Coverage: 600998's debt is well covered by operating cash flow (25.8%).
Interest Coverage: 600998's interest payments on its debt are well covered by EBIT (4x coverage).